Tagged with Strategy

Denmark Europe lags behind the US in terms of biotech success stories, but one company bucking that trend is Denmark-headquartered Genmab, with a market cap of over USD 25 billion. Dual-listed on the Copenhagen stock exchange and on NASDAQ in the US, there are five products based on Genmab science on…

Denmark Speaking exclusively to PharmaBoardroom, Jan van de Winkel highlights the tremendous progress that European biotech success story Genmab has made over the past six years, how its partnership model is evolving, Denmark’s continuing relevance to the company, and Genmab’s value proposition for the next generation of talent.   Genmab has…

Denmark Speaking after the recent completion of a three-year strategic transformation plan, ALK President and CEO Carsten Hellmann outlines the progress made by the Danish allergy giant under his stewardship, including deeper penetration of the US market, shifting from injections to tablets, and driving digitalisation and efficiency.   To put our…

Saudi Arabia Maher Elhassan, Beckton Dickinson’s VP and general manager for the Middle East, North Africa, and Turkey (MENAT), comments on the company’s important role during the COVID-19 pandemic – including the provision of diagnostic tools and syringes for vaccination – and reveals why BD was the first medical technology company to…

Saudi Arabia Medtronic’s country director for Saudi Arabia, Mohammed El Ansari, comments on the implications of the company’s decision to move to a direct presence in the Kingdom, positioning the affiliate as a career launchpad for local talent, the local manufacturing of ventilators, and why Medtronic considers Saudi Arabia a priority market.…

Saudi Arabia Sameh ElFangary, Country President for GCC and Pakistan at AstraZeneca, highlights AstraZeneca’s alignment with, and commitment to, Saudi Arabia’s Vision 2030 and the opportunities that the Vision is creating. ElFangary also explains the significance of a new memorandum of understanding to create a clinical research hub in Riyadh and how…

Saudi Arabia Ipsen’s general manager for Middle East and Africa (MEA), Khaled Elrefae, highlights the French firm’s expanding footprint in the region, the fundamentals that make MEA a growth driver for Ipsen, and the opportunities for further growth from its oncology, rare disease and neuroscience portfolios. In addition, Elrefae discusses the changing…

Switzerland Luye Pharma is a China-headquartered fully integrated oncology and CNS specialist. Bruno Delie, general manager for Switzerland, discusses the organization’s ambitious European expansion plan, looking to establish affiliates in the top five markets within the continent in order to introduce four or five new products from their pipeline in the…

Denmark In a wide-ranging and candid conversation, Siemens Healthineers’ Tisha Boatman discusses uprooting from the US to Denmark, how Danish hospital tendering needs to evolve beyond price considerations alone, the challenges and opportunities of the Varian integration in her region, and shares some advice for other female executives in the medtech…

Saudi Arabia After almost two decades with MSD, Ashraf Mallak, managing director for the company in the GCC region, dives into the often-overlooked healthcare capabilities of the Gulf countries, including the fact that certain products approved by the US FDA can sometimes be available in the region in as little as one…

Denmark Speaking after the recent completion of a three-year strategic transformation plan, ALK President and CEO Carsten Hellmann outlines the progress made by the Danish allergy giant under his stewardship, including deeper penetration of the US market, shifting from injections to tablets, and driving digitalisation and efficiency. Hellmann also outlines the…

UK The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over 1,000 new jobs at its facilities in Northern Ireland over the next three years.   AstraZeneca to create dedicated Covid…